The Burrill Report's Advisory board is made up of leading academics, biopharmaceutical executives, and medical technology innovators, along with leaders in finance and venture capital.

EDITORIAL ADVISORY BOARD MEMBERS

BUSINESS ADVISORY BOARD MEMBERS

• Joel S. Marcus CEO, Alexandria Real Estate Equities, Inc.
• Peter Barton Hutt Partner, Covington & Burling
• G. Steven Burrill CEO, Burrill & Company
• Brook Byers Partner, Kleiner Perkins Caufield & Byers
• Peter Farrell CEO, ResMed
• Fred Frank Vice Chairman, Lehman Brothers
• Matthew Hudes National Managing Principal, Biotechnology, Deloitte Consulting LLP

SCIENCE

• Anthony Atala Director, Inst. for Regenerative Medicine, Wake Forest Institute
• David Baltimore Professor of Biology and Nobel Laureate, Caltech
• Richard Burt Head of Department of Immunology, Northwestern University
• Ron Evans March of Dimes Chair in Developmental and Molecular Biology, The Salk Institute
• Edward Holmes Executive Deputy Chairman, Singapore's Agency for Science, Technology & Research
• Lee Hood Founder & Director of Medicine, The Institute for Systems Biology
• Philip Pizzo Dean, School of Medicine, Stanford University
• George Post Chief Scientist, Complex Adaptive Systems Initiative; Regents' Professor and Del E. Webb Distinguished Professor of Biology, Arizona State University, Skysong
• Harriet Wallberg-Henricksson President, Karolinska Institute for Regenerative Medicine, Sweden

INDUSTRY

• David Beier Senior Vice President, Global Government Affairs, Amgen
• Susan Desmond-Hellmann President, Product Development, Genentech
• David Gollaher President & CEO, California Healthcare Institute
• Ginger Graham Former President & CEO, Amylin Pharmaceuticals
• Robert Klein Chairman, Independent Citizens Oversight Committee,
• David Lawrence Former CEO & Chairman, Kaiser
• Ted Love Chairman & CEO, Nuvelo
• Greg Lucier Chairman & CEO, Invitrogen
• John Martin Chairman & CEO, Gilead Sciences
• Hank Nordhoff Chairman and CEO, Gen-Probe